In a small Phase IIa trial, Insilico’s generative AI-designed idiopathic pulmonary fibrosis drug improved lung function and ...
Recent developments driving growth in this area make the advanced, AI-supported digitization of pharma pipelines inevitable.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback